Basic Information
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapies. The company's broad portfolio targets various cancer drivers, including a novel oncology discovery program centered on Fragile X Mental Retardation Protein (FMRP) and a diversified pipeline of validated oncology assets acquired from Plexxikon.